Notice of Intent To Prepare an Environmental Impact Statement for the Transport of Laboratory Personnel Exposed to Infectious Agents From Fort Detrick, Frederick, MD to the National Institutes of Health Clinical Center, Bethesda, MD, 35145-35146 [E8-14033]
Download as PDF
<![CDATA[
35145
Federal Register / Vol. 73, No. 120 / Friday, June 20, 2008 / Notices
2007 HHS POVERTY GUIDELINES—Continued
48 contiguous
states and DC
Persons in family or household
For each additional person, add ............................................................................................
Alaska
3,480
Hawaii
4,350
4,000
Source: FEDERAL REGISTER, Vol. 72, No. 15, January 24, 2007, pp. 3147–3148.
These guidelines are updated
periodically.
Criteria for Donor Reimbursement
1. Any individual who in good faith
incurs travel and other qualifying
expenses toward the intended donation
of an organ.
2. Donor and recipient of the organ
are U.S. citizens or lawfully admitted
residents of the U.S.
3. Donor and recipient have primary
residences in the U.S. or its territories.
4. Travel is originating from the
donor’s primary residence.
5. Donor and recipient certify that
they understand and are in compliance
with Section 301 of NOTA (42 U.S.C.
274e) which states in part ‘‘* * * . It
shall be unlawful for any person to
knowingly acquire, receive, or otherwise
transfer any human organ for valuable
consideration for use in human
transplantation if the transfer affects
interstate commerce.’’
6. The transplant center where the
donation procedure occurs certifies to
its status of good standing with the
Organ Procurement and Transplantation
Network (OPTN).
jlentini on PROD1PC65 with NOTICES
Qualifying Expenses
For the purposes of the
Reimbursement of Travel and
Subsistence Expenses toward Living
Organ Donation Program, qualifying
expenses presently include only travel,
lodging, and meals and incidental
expenses incurred by the donor and/or
his/her accompanying person(s) as part
of:
(1) Donor evaluation, clinic visit or
hospitalization,
(2) Hospitalization for the living
donor surgical procedure, and/or
(3) Medical or surgical follow-up
clinic visit or hospitalization within 90
days following the living donation
procedure.
The Program will pay for a total of up
to five trips; three for the donor and two
for accompanying persons. However, in
cases in which the transplant center
requests the donor to return to the
transplant center for additional visits as
a result of donor complications or other
health related issues, NLDAC may
provide reimbursement for the
additional visit(s) for the donor and an
accompanying person. The
VerDate Aug<31>2005
16:53 Jun 19, 2008
Jkt 214001
accompanying persons need not be the
same in each trip.
The total Federal reimbursement for
qualified expenses during the donation
process for the donor and accompanying
individuals shall not exceed $6,000.00.
Reimbursement for qualifying expenses
shall be provided at the Federal perdiem rate, except for hotel
accommodation, which shall be
reimbursed at no more than 150 percent
of the Federal per-diem rate.
For donor and recipient pairs
participating in a paired exchange
program, the applicable eligibility
criteria for the originally intended
recipient shall be considered for the
purpose of reimbursement of qualifying
donor expenses even though the final
recipient of the donated organ may not
be the recipient identified in the
original donor-recipient pair.
Maximum Number of Prospective
Donors per Recipient
• Kidney: One donor at a time with
a maximum of three donors.
• Liver: One donor at a time with a
maximum of five donors.
• Lung: Two donors at a time with a
maximum of six donors.
Special Provisions
Many factors may prevent the
intended and willing donor from
proceeding with the donation.
Circumstances that would prevent the
transplant or donation from proceeding
include: present health status of the
intended donor or recipient, perceived
long-term risks to the intended donor,
justified circumstances such as acts of
God (e.g., major storms or hurricanes),
or a circumstance when an intended
donor proceeds toward donation in
good faith, subject to a case-by-case
evaluation by the NLDAC, but then
elects not to pursue donation. In such
cases, the intended donor and
accompanying persons may receive
reimbursement for qualified expenses
incurred as if the donation had been
completed. Under Program policy, a
form will be filed with the Internal
Revenue Service (IRS) reporting funds
disbursed as income for expenses not
incurred.
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Dated: June 13, 2008.
Elizabeth M. Duke,
Administrator.
[FR Doc. E8–14036 Filed 6–19–08; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Intent To Prepare an
Environmental Impact Statement for
the Transport of Laboratory Personnel
Exposed to Infectious Agents From
Fort Detrick, Frederick, MD to the
National Institutes of Health Clinical
Center, Bethesda, MD
SUMMARY: In accordance with the
National Environmental Policy Act, 42
U.S.C. 4321–4347, the NIH is issuing
this notice to advise the public that an
environmental impact statement will be
prepared for the transport of laboratory
personnel exposed to infectious agents
from Fort Detrick, Frederick, Maryland
to the National Institutes of Health
Clinical Center, Bethesda, Maryland.
FOR FURTHER INFORMATION CONTACT:
Valerie Nottingham, Chief,
Environmental Quality Branch, Division
of Environmental Protection, Office of
Research Facilities, NIH, B13/2S11,
9000 Rockville Pike, Bethesda,
Maryland 20892, telephone 301–496–
7775; fax 301–480–8056; or e-mail
nihnepa@mail.nih.gov.
SUPPLEMENTARY INFORMATION: Fort
Detrick is a U.S. Army Medical
Command installation located in
Frederick, Maryland, USA. Its 1,200
acres support a multi-governmental
community that conducts biomedical
research and development, medical
material management, global medical
communications and the study of
foreign plant pathogens. It is home to
the U.S. Army Medical Research and
Materiel Command (USAMRMC), with
its U.S. Army Medical Research
Institute of Infectious Diseases
(USAMRIID), as well as to the National
Cancer Institute-Frederick (NCIFrederick). It is the home of the National
Interagency Biodefense Campus.
The National Institute of Allergy and
Infectious Diseases (NIAID), a
component of NIH, will be the occupant
E:\FR\FM\20JNN1.SGM
20JNN1
jlentini on PROD1PC65 with NOTICES
35146
Federal Register / Vol. 73, No. 120 / Friday, June 20, 2008 / Notices
of an Integrated Research Facility (IRF)
currently being built at Fort Detrick as
part of the National Interagency
Biodefense Campus. The IRF will
contain bio-safety level -2, -3, and -4
laboratory and animal research facilities
for conducting biodefense and emerging
infectious disease research. This
laboratory will allow NIH to address a
critical national shortage in bio-safety
level-4 (BSL–4) capability.
The Clinical Center at the National
Institutes of Health (NIH) in Bethesda,
Maryland, is the nation’s largest
hospital devoted entirely to clinical
research. It is a national resource that
makes it possible to rapidly translate
scientific observations and laboratory
discoveries into new approaches for
diagnosing, treating, and preventing
disease. Approximately 1,500 studies
are in progress at the NIH Clinical
Center. Most are Phase I and Phase II
clinical trials.
More than 350,000 patients, from all
50 states and throughout the world,
have participated in clinical research at
the Clinical Center since it opened in
1953. The Clinical Center promotes
translational research—that is, the
transference of scientific laboratory
research into applications that benefit
patient health and medical care. The
‘‘bench-to-bedside’’ approach adopted
in 1953 locates patient care units in
close proximity to cutting-edge
laboratories doing related research. This
facilitates interaction and collaboration
among clinicians and researchers. Most
important, patients and families in the
Clinical Center benefit from the cuttingedge technologies and research and the
compassionate care that are the
signature of the NIH.
The Mark O. Hatfield Clinical
Research Center (CRC) was opened in
2005. The facility houses inpatient
units, day hospitals and research labs
and connects to the original Warren
Grant Magnuson Clinical Center.
Together, the Magnuson and Hatfield
buildings form the NIH Clinical Center.
They serve the dual role of providing
humane and healing patient care and
the environment clinical researchers
need to advance clinical science. The
870,000-square-foot Hatfield building
has 242 inpatient beds and 90 dayhospital stations. This arrangement can
be easily adapted to allow more
inpatient beds and fewer day-hospital
stations, or vice versa, because the new
facility’s design is highly flexible. The
facility has unique ventilation systems
that are designed to minimize the
spread of infectious disease within the
facility and includes isolation rooms
equipped with special filtering and
containment features.
VerDate Aug<31>2005
16:53 Jun 19, 2008
Jkt 214001
The proposed action is to transport
laboratory personnel in the event of
potential exposure to infectious agents
from the Fort Detrick Campus to the
NIH Clinical Center for monitoring,
evaluation, and if necessary,
treatment.The CRC is well-equipped to
deal with such scenarios, unlikely as
they are.
In accordance with 40 CFR 1500–1508
and DHHS environmental procedures,
NIH will prepare an Environmental
Impact Statement (EIS) for the proposed
transport of laboratory personnel
exposed to infectious agents from the
Fort Detrick Campus to the NIH Clinical
Center for monitoring, evaluation, and if
necessary, treatment.
Among the items the EIS will examine
are the implications of the proposed
action on human health, traffic and
transportation, and other public
services. To ensure that the public is
afforded the greatest opportunity to
participate in the planning and
environmental review process, NIH is
inviting oral and written comments on
the proposed action and related
environmental issues.
The NIH will be sponsoring two
public Scoping Meetings to provide
individuals an opportunity to share
their ideas on the proposed action,
including recommended alternatives
and environmental issues the EIS
should consider. The first meeting is
planned for 6:30 p.m. on July 8, 2008 at
the C. Burr Artz Library, 110 East
Patrick Street, Frederick, Maryland
21701. The second meeting is planned
for 7 p.m. on July 10, 2008 at the
Bethesda-Chevy Chase Service Center,
4805 Edgemoor Lane, Bethesda,
Maryland 20814. All interested parties
are encouraged to attend. NIH has
established a 45-day public comment
period for the scoping process. Scoping
comments must be postmarked no later
than August 8, 2008 to ensure they are
considered. All comments and
questions on the EIS should be directed
to Valerie Nottingham at the address
listed above, telephone 301–496–7775;
fax 301–480–8056; or e-mail
nihnepa@mail.nih.gov.
Dated: June 13, 2008.
Daniel Wheeland,
Director, Office of Research Facilities
Development and Operations, National
Institutes of Health.
[FR Doc. E8–14033 Filed 6–19–08; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; NIH Support for
Conferences and Scientific Meetings Special
Emphasis Panel.
Date: July 2, 2008.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Prabha L. Atreya, PhD,
Scientific Review Administrator, Office of
Scientific Review, National Institute of
Biomedical Imaging and Bioengineering,
Bethesda, MD 20892, (301) 496–8633,
atreyapr@mail.nih.gov.
Dated: June 13, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–13905 Filed 6–19–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[FEMA–1766–DR]
Indiana; Major Disaster and Related
Determinations
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is a notice of the
Presidential declaration of a major
Frm 00031
Fmt 4703
Sfmt 4703
E:\FR\FM\20JNN1.SGM
20JNN1
]]>Agencies
[Federal Register Volume 73, Number 120 (Friday, June 20, 2008)]
[Notices]
[Pages 35145-35146]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-14033]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Intent To Prepare an Environmental Impact Statement for
the Transport of Laboratory Personnel Exposed to Infectious Agents From
Fort Detrick, Frederick, MD to the National Institutes of Health
Clinical Center, Bethesda, MD
SUMMARY: In accordance with the National Environmental Policy Act, 42
U.S.C. 4321-4347, the NIH is issuing this notice to advise the public
that an environmental impact statement will be prepared for the
transport of laboratory personnel exposed to infectious agents from
Fort Detrick, Frederick, Maryland to the National Institutes of Health
Clinical Center, Bethesda, Maryland.
FOR FURTHER INFORMATION CONTACT: Valerie Nottingham, Chief,
Environmental Quality Branch, Division of Environmental Protection,
Office of Research Facilities, NIH, B13/2S11, 9000 Rockville Pike,
Bethesda, Maryland 20892, telephone 301-496-7775; fax 301-480-8056; or
e-mail nihnepa@mail.nih.gov.
SUPPLEMENTARY INFORMATION: Fort Detrick is a U.S. Army Medical Command
installation located in Frederick, Maryland, USA. Its 1,200 acres
support a multi-governmental community that conducts biomedical
research and development, medical material management, global medical
communications and the study of foreign plant pathogens. It is home to
the U.S. Army Medical Research and Materiel Command (USAMRMC), with its
U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID),
as well as to the National Cancer Institute-Frederick (NCI-Frederick).
It is the home of the National Interagency Biodefense Campus.
The National Institute of Allergy and Infectious Diseases (NIAID),
a component of NIH, will be the occupant
[[Page 35146]]
of an Integrated Research Facility (IRF) currently being built at Fort
Detrick as part of the National Interagency Biodefense Campus. The IRF
will contain bio-safety level -2, -3, and -4 laboratory and animal
research facilities for conducting biodefense and emerging infectious
disease research. This laboratory will allow NIH to address a critical
national shortage in bio-safety level-4 (BSL-4) capability.
The Clinical Center at the National Institutes of Health (NIH) in
Bethesda, Maryland, is the nation's largest hospital devoted entirely
to clinical research. It is a national resource that makes it possible
to rapidly translate scientific observations and laboratory discoveries
into new approaches for diagnosing, treating, and preventing disease.
Approximately 1,500 studies are in progress at the NIH Clinical Center.
Most are Phase I and Phase II clinical trials.
More than 350,000 patients, from all 50 states and throughout the
world, have participated in clinical research at the Clinical Center
since it opened in 1953. The Clinical Center promotes translational
research--that is, the transference of scientific laboratory research
into applications that benefit patient health and medical care. The
``bench-to-bedside'' approach adopted in 1953 locates patient care
units in close proximity to cutting-edge laboratories doing related
research. This facilitates interaction and collaboration among
clinicians and researchers. Most important, patients and families in
the Clinical Center benefit from the cutting-edge technologies and
research and the compassionate care that are the signature of the NIH.
The Mark O. Hatfield Clinical Research Center (CRC) was opened in
2005. The facility houses inpatient units, day hospitals and research
labs and connects to the original Warren Grant Magnuson Clinical
Center. Together, the Magnuson and Hatfield buildings form the NIH
Clinical Center. They serve the dual role of providing humane and
healing patient care and the environment clinical researchers need to
advance clinical science. The 870,000-square-foot Hatfield building has
242 inpatient beds and 90 day-hospital stations. This arrangement can
be easily adapted to allow more inpatient beds and fewer day-hospital
stations, or vice versa, because the new facility's design is highly
flexible. The facility has unique ventilation systems that are designed
to minimize the spread of infectious disease within the facility and
includes isolation rooms equipped with special filtering and
containment features.
The proposed action is to transport laboratory personnel in the
event of potential exposure to infectious agents from the Fort Detrick
Campus to the NIH Clinical Center for monitoring, evaluation, and if
necessary, treatment.The CRC is well-equipped to deal with such
scenarios, unlikely as they are.
In accordance with 40 CFR 1500-1508 and DHHS environmental
procedures, NIH will prepare an Environmental Impact Statement (EIS)
for the proposed transport of laboratory personnel exposed to
infectious agents from the Fort Detrick Campus to the NIH Clinical
Center for monitoring, evaluation, and if necessary, treatment.
Among the items the EIS will examine are the implications of the
proposed action on human health, traffic and transportation, and other
public services. To ensure that the public is afforded the greatest
opportunity to participate in the planning and environmental review
process, NIH is inviting oral and written comments on the proposed
action and related environmental issues.
The NIH will be sponsoring two public Scoping Meetings to provide
individuals an opportunity to share their ideas on the proposed action,
including recommended alternatives and environmental issues the EIS
should consider. The first meeting is planned for 6:30 p.m. on July 8,
2008 at the C. Burr Artz Library, 110 East Patrick Street, Frederick,
Maryland 21701. The second meeting is planned for 7 p.m. on July 10,
2008 at the Bethesda-Chevy Chase Service Center, 4805 Edgemoor Lane,
Bethesda, Maryland 20814. All interested parties are encouraged to
attend. NIH has established a 45-day public comment period for the
scoping process. Scoping comments must be postmarked no later than
August 8, 2008 to ensure they are considered. All comments and
questions on the EIS should be directed to Valerie Nottingham at the
address listed above, telephone 301-496-7775; fax 301-480-8056; or e-
mail nihnepa@mail.nih.gov.
Dated: June 13, 2008.
Daniel Wheeland,
Director, Office of Research Facilities Development and Operations,
National Institutes of Health.
[FR Doc. E8-14033 Filed 6-19-08; 8:45 am]
BILLING CODE 4140-01-P
